Drug Profile
BL 7040
Alternative Names: BL7040Latest Information Update: 01 Aug 2019
Price :
$50
*
At a glance
- Originator Hebrew University of Jerusalem; Yissum Research Development Company
- Developer BioLineRx; Ester Neurosciences
- Class Anti-inflammatories; Oligonucleotides
- Mechanism of Action Acetylcholinesterase inhibitors; Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Myasthenia gravis; Ulcerative colitis
Most Recent Events
- 27 Aug 2015 BL 7040 is still in phase-II development for Ulcerative colitis in Israel
- 17 Mar 2014 BL 7040 is available for licensing as of 17 Mar 2014. http://www.biolinerx.com/
- 17 Mar 2014 Adverse events data from preclinical studies released in the BioLineRx Form 20-F